Cancer Research Campaign Clinical Trials Centre
8
0
0
6
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 25/100
0.0%
0 terminated/withdrawn out of 8 trials
100.0%
+13.5% vs industry average
88%
7 trials in Phase 3/4
0%
0 of 6 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (8)
Hyperthermia and Mitomycin C, Bacillus Calmette-Guerin, or Standard Therapy as Second-Line Therapy in Treating Patients With Recurrent Bladder Cancer
Role: lead
Warfarin in Preventing Blood Clots in Cancer Patients With Central Venous Catheters
Role: lead
Combination Chemotherapy in Treating Women With Breast Cancer Who Have Undergone Surgery
Role: lead
Combination Chemotherapy in Treating Older Patients With Intermediate- or High-Grade Non-Hodgkin's Lymphoma
Role: lead
Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma
Role: lead
Exemestane Compared With Tamoxifen in Treating Postmenopausal Women With Breast Cancer
Role: lead
Tamoxifen, Ovarian Ablation, and/or Chemotherapy in Treating Women With Stage I, Stage II, or Stage IIIA Breast Cancer
Role: collaborator
Rofecoxib After Surgery in Treating Patients With Stage II or Stage III Colorectal Cancer
Role: lead
All 8 trials loaded